PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...
Main Authors: | K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova |
---|---|
Format: | Article |
Language: | English |
Published: |
Paediatrician Publishers, LLC
2012-08-01
|
Series: | Pediatričeskaâ Farmakologiâ |
Subjects: | |
Online Access: | https://www.pedpharma.ru/jour/article/view/302 |
Similar Items
-
ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-12-01) -
EXPERIENCE OF THE ADALIMUMAB APPLICATION FOR THE PATIENT WITH EARLY DEBUT OF JUVENILE IDIOPATHIC ARTHRITIS AND UVEITIS
by: K. B. Isaeva, et al.
Published: (2014-07-01) -
EXPERIENCE OF APPLYING MONOCLONAL ANTIBODIES TO TNF α — ADALIMUMAB — IN A CHILD WITH JUVENILE IDIOPATHIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013-07-01) -
The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study
by: E. V. Gaidar, et al.
Published: (2016-11-01) -
Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age
by: Ekaterina Alexeeva, et al.
Published: (2020-07-01)